EP Patent

EP3613436A1 — Oral suspension of temozolomide

Assigned to Orphelia Pharma · Expires 2020-02-26 · 6y expired

What this patent protects

The present invention concerns a pharmaceutical composition, advantageously a liquid suspension, comprising:a. temozolomide or a salt thereof;b. at least one agent controlling the solid state of temozolomide in suspension;c. a pharmaceutically acceptable liquid vehicle, advantage…

USPTO Abstract

The present invention concerns a pharmaceutical composition, advantageously a liquid suspension, comprising:a. temozolomide or a salt thereof;b. at least one agent controlling the solid state of temozolomide in suspension;c. a pharmaceutically acceptable liquid vehicle, advantageously water;d. optionally at least one acid in a quantity so that the pH of the composition is below 5;or a powder blend for reconstituting said suspension.

Drugs covered by this patent

Patent Metadata

Patent number
EP3613436A1
Jurisdiction
EP
Classification
—
Expires
2020-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Orphelia Pharma
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.